Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection

Keyphrases

• Patient Selection 100%
• Psoriatic Arthritis 100%
• Safety Efficacy 100%
• Safety Patient 100%
• Ixekizumab 100%
• Injection Site Reaction 25%
• Adalimumab 25%
• Randomized Controlled Trial 16%
• Placebo 16%
• Monoclonal Antibody 8%
• High Risk 8%
• Disease Progression 8%
• Interleukin-17 (IL-17) 8%
• Inclusion Criteria 8%
• PubMed 8%
• Disease Activity 8%
• Serious Adverse Events 8%
• African American Studies 8%
• Antibody Targeting 8%
• Psoriasis 8%
• Allergic Reaction 8%
• Activity Domains 8%
• Arthritis Diseases 8%
• Lack of Representation 8%
• Long-term Extension Study 8%
• Axial Spondyloarthritis (AxSpA) 8%

Immunology and Microbiology

• Psoriatic Arthritis 100%
• Ixekizumab 100%
• Adalimumab 25%
• Monoclonal Antibody 8%
• Medline 8%
• Hypersensitive Response 8%